Literature DB >> 19141057

Insight into the mechanisms underlying tumor response to boron neutron capture therapy in the hamster cheek pouch oral cancer model.

Romina F Aromando1, Elisa M Heber, Verónica A Trivillin, David W Nigg, Amanda E Schwint, María E Itoiz.   

Abstract

OBJECTIVE: The therapeutic success of different boron neutron capture therapy (BNCT) protocols employing the hamster cheek pouch oral cancer model has been previously reported by our laboratory. The aim of this study was to explore potential mechanisms of BNCT-induced damage to tumor in terms of potential inhibition in DNA synthesis and induction of apoptosis in the tumors that underwent partial remission following application of the different BNCT protocols in this model.
MATERIALS AND METHODS: We evaluated DNA synthesis employing incorporation of 5-bromo-2'-deoxyuridine as an end-point. Apoptosis was evaluated by immunohistochemistry employing the deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end-labeling technique and Bax and Bcl-2 labeling. These studies were performed in tumors that underwent partial remission 1-30 days post-BNCT mediated by boronophenylalanine (BPA), GB-10 (Na(2)(10)B(10)H(10)) or (BPA + GB-10).
RESULTS: BNCT exerted a marked inhibitory effect on DNA synthesis in tumors for all the protocols under study. The inhibitory effect of BPA-BNCT occurred as soon as 1 day post-treatment (P < 0.001). Conversely, the effect of GB-10-BNCT became apparent 7-14 days after therapy (P < 0.001) and was sustained until killed at 30 days post-treatment (P < 0.001). (GB-10 + BPA)-BNCT exerted a rapid and persistent effect, conceivably because of the combined effect of BNCT mediated by both boron compounds. The apoptosis studies did not show differences between the pre-treatment group and any of the BNCT groups.
CONCLUSIONS: One of the mechanisms involved in BNCT-induced tumor control in our model would be an inhibitory effect on DNA synthesis. Apoptosis does not seem to have a significant role in BNCT-induced tumor control in our model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19141057     DOI: 10.1111/j.1600-0714.2008.00720.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  5 in total

1.  Boron neutron capture therapy (BNCT) translational studies in the hamster cheek pouch model of oral cancer at the new "B2" configuration of the RA-6 nuclear reactor.

Authors:  Andrea Monti Hughes; Juan Longhino; Esteban Boggio; Vanina A Medina; Diego J Martinel Lamas; Marcela A Garabalino; Elisa M Heber; Emiliano C C Pozzi; María E Itoiz; Romina F Aromando; David W Nigg; Verónica A Trivillin; Amanda E Schwint
Journal:  Radiat Environ Biophys       Date:  2017-09-04       Impact factor: 1.925

2.  Abscopal effect of boron neutron capture therapy (BNCT): proof of principle in an experimental model of colon cancer.

Authors:  Verónica A Trivillin; Emiliano C C Pozzi; Lucas L Colombo; Silvia I Thorp; Marcela A Garabalino; Andrea Monti Hughes; Sara J González; Rubén O Farías; Paula Curotto; Gustavo A Santa Cruz; Daniel G Carando; Amanda E Schwint
Journal:  Radiat Environ Biophys       Date:  2017-08-08       Impact factor: 1.925

3.  Boron neutron capture therapy induces apoptosis of glioma cells through Bcl-2/Bax.

Authors:  Peng Wang; Haining Zhen; Xinbiao Jiang; Wei Zhang; Xin Cheng; Geng Guo; Xinggang Mao; Xiang Zhang
Journal:  BMC Cancer       Date:  2010-12-02       Impact factor: 4.430

4.  Role of p53 mutation in the effect of boron neutron capture therapy on oral squamous cell carcinoma.

Authors:  Yusei Fujita; Itsuro Kato; Soichi Iwai; Koji Ono; Minoru Suzuki; Yoshinori Sakurai; Ken Ohnishi; Takeo Ohnishi; Yoshiaki Yura
Journal:  Radiat Oncol       Date:  2009-12-11       Impact factor: 3.481

5.  Apoptosis through Bcl-2/Bax and cleaved caspase up-regulation in melanoma treated by boron neutron capture therapy.

Authors:  Fernanda Faião-Flores; Paulo Rogério Pinto Coelho; João Dias Toledo Arruda-Neto; Silvya Stuchi Maria-Engler; Manoela Tiago; Vera Luiza Capelozzi; Ricardo Rodrigues Giorgi; Durvanei Augusto Maria
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.